Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia

NCT: NCT07658898 · NOT_YET_RECRUITING

NCT IDNCT07658898
StatusNOT_YET_RECRUITING
Start Date2026-06-30
Completion2027-12-30
SponsorShanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University (OTHER)
First posted
Last updated

Brief Summary

This randomized, double-blind, sham-controlled trial aims to evaluate the efficacy and safety of dorsal anterior cingulate cortex-targeted temporal interference stimulation in individuals with schizophrenia. Participants will be randomly assigned to receive either active or sham stimulation for 10 sessions over two consecutive weeks. The primary outcome is the change in negative symptoms, assessed using the Negative Symptom Subscale of the Positive and Negative Syndrome Scale. Cognitive performance, detailed dimensions of negative symptoms, psychosocial functioning, quality of life, and treatment-related adverse events will also be evaluated. Neuroimaging assessments will be conducted before and after the intervention to explore potential neural mechanisms underlying the clinical effects of temporal interference stimulation.

Frequently Asked Questions

What is dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia?

dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia is a clinical trial registered under NCT07658898. Current status: NOT_YET_RECRUITING.

What is the status of NCT07658898?

The current status of NCT07658898 (dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia) is: NOT_YET_RECRUITING.

When did dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia start?

dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia started on 2026-06-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.